Divergence of HTA Decisions Across Countries: Case Analysis of Ivabradine
2013 Value in health
Thivolet, M. | Remuzat, C. | Kornfeld, A. | Toumi, M. |
In 2012, ivabradine was centrally approved by the EMA for Chronic Heart Failure treatment. Through ivabradine NICE and HAS decisions analysis, the objective of this policy research is to illustrate the divergence of HTA decisions despite a consistent efficacy, effectiveness and economics information.